Skip to main
HIMS

HIMS Stock Forecast & Price Target

HIMS Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 21%
Buy 14%
Hold 64%
Sell 0%
Strong Sell 0%

Bulls say

Hims & Hers Health is a telehealth platform that is making waves in the healthcare industry. The company has a diversified portfolio of treatments and medications, and with more than 2 million subscribers, it has a wide reach. The recent partnership with Novo Nordisk, which includes the sale of the Wegovy pill, presents significant revenue potential for Hims & Hers. Additionally, the company's expansion into international markets and vertical integration efforts provide opportunities for long-term growth. The current regulatory and legal risks should not overshadow Hims & Hers' strong base and potential for growth.

Bears say

Hims & Hers Health is facing potential risks and regulation challenges in their compounded products, as well as potential litigation risks. However, their partnership with Novo Nordisk and expansion into new specialties and international markets show potential for increased revenue and margins, leading to a Buy rating and a $30 price target. Despite a cautious approach from analysts, Hims & Hers Health maintains positive relationships in the healthcare industry and expects growth in various areas, such as online orders and wholesale revenue.

HIMS has been analyzed by 14 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 14% recommend Buy, 64% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hims & Hers Health (HIMS) Forecast

Analysts have given HIMS a Buy based on their latest research and market trends.

According to 14 analysts, HIMS has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hims & Hers Health (HIMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.